J. Goldman & Co’s Elevation Oncology ELEV Stock Holding History

J. Goldman & Co’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,500	Closed	-$20.5K	–	392
2023 Q2	$20.5K	Buy	+13,500	New	+$35.6K	﹤0.01%	359

Other funds holding ELEV

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

J. Goldman & Co's ELEV Position: Q3 2023 in Review

J. Goldman & Co sold out of Elevation Oncology (ELEV) in Q3 2023, closing a stake of 13,500 shares — an estimated $20.5K sold.

J. Goldman & Co first reported a position in ELEV in Q2 2023 and held it in 1 quarter. The position peaked at $20.5K in Q2 2023. 41 funds tracked by Wall St. Rank hold ELEV as of Q3 2023.

J. Goldman & Co reported no remaining Elevation Oncology position as of Q3 2023 after selling out during the quarter.
J. Goldman & Co sold 13,500 Elevation Oncology shares in Q3 2023, an estimated $20.5K.
J. Goldman & Co first reported a position in Elevation Oncology in Q2 2023 and held it in 1 quarter.
J. Goldman & Co's Elevation Oncology position peaked at $20.5K in Q2 2023.
41 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.